Active immunization is effective in the prophylaxis of Pseudomonas septicemia in burned mice. Vaccines were prepared from bacterial cells and growth medium of Verder's 10 different 0 serological types of Pseudomonas aeruginosa strains, as well as from Escherichia coli and Proteus mirabilis. Mice given a tail burn could be significantly protected against a local Pseudomonas challenge by both specific and, to a lesser extent, by nonspecific Pseudomonas vaccines prepared either from bacterial cells or from the medium in which they were grown. The vaccine was effective when administered prior to or after thermal trauma. After a more extensive rump burn, the protective effect of a specific vaccine given after thermal injury was significant only when the challenge was postponed until 4 days postburn; the level of protection was less than in the mice with smaller burns.
Since the most prevalent cause of death in man after thermal injury is now gram-negative septicemia, and especially Pseudomonas septicemia (7, 10, 15) , we have been studying means by which to combat these infections in burned animals. Recent progress has been made in the prevention of overwhelming infection in burned patients by the application of topical chemotherapeutic agents, such as mafenide hydrochloride, silver nitrate, and gentamicin (7, 14, 17) . However, most of these agents have defects in that they may cause serious electrolyte disturbances, pulmonary complications, allergic responses, and other toxic manifestations (7, 14) . Most important of all, some patients who have been treated with these agents still die as a result of generalized infections, probably due to the emergence of resistant bacteria. The problem of resistance may become even more serious with the passage of time.
We have approached the problem of infection by studying active immunization in burned mice as a means of preventing death due to Pseudomonas septicemia. Surprisingly little has been published about the prophylaxis of Pseudomonas infections by vaccination in humans (2, (4) (5) (6) or experimental animals (3, 13, 20) . Previously, we reported that burned mice were protected against an intraperitoneal P. aeruginosa challenge by vaccinations of killed P. aeruginosa organisms administered before or after the burn (13) . The present report extends that study but differs in that (i) we investigated the effect of vaccination of mice with burns of increasing severity; (ii) we challenged burned mice locally, rather than intraperitoneally, to simulate the pathogenesis of human infection; (iii) we studied the effect of specific, as well as nonspecific, vaccines in burned mice challenged with Pseudomonas; and (iv) we prepared vaccines from both bacterial cells and from the medium in which they were grown.
Our results demonstrate that specific, as well as nonspecific, vaccination is a useful prophylactic agent in burned mice challenged with P. aeruginosa.
MATERIALS AND METHODS
Animals. Conventional, female (18 to 20 g) National Institutes of Health stock or general purpose albino, Swiss-Webster mice were used in all of these experiments.
Types of thermal trauma studied. All mice were anesthetized with diethyl ether prior to the following burns of increasing severity: (i) tail bum, the tail was immersed in water at 70 C for 5 sec and then dabbed dry (16) ; and (ii) rump burn, the mouse was immersed in water to the level slightly above the genitalia at 70 C for 3 or 5 sec and then dabbed dry.
After the burn, groups of 10 animals were placed in a plastic shoe box-type cage (29 X 18 cm). Mice were allowed Purina laboratory chow and water ad libitum.
The tail burn without challenge caused no 21-day mortality. The same burn with 0.1 ml of vaccine given afterward, but again without challenge, produced less than a 1% 21-day mortality. The Table 2 gives the results of the same type of experiment, but in this case using vaccines prepared from the medium in which the bacteria had been growing. The 21-day mortality rate of these controls, which received brain heart broth, was 71%. As with the vaccines prepared from cells, the supernatant vaccines prepared from the specific organism (P. aeruginosa 180) showed the lowest mortality of 4% at 21 days, but the supernatant vaccine from all other 0 antigenic types also produced a significant lowering of mortality, varying between 8 and 43% (P < 0.001). Again, E. coli and Proteus mirabilis supernatant vaccines showed a significant nonspecific protective effect (P < 0.05).
In many cases, the vaccine prepared from the medium produced a lower mortality than the vaccine prepared from the cells, but the difference between the two did not show statistical significance (P > 0.05). The good protective effect observed with the vaccine prepared from the medium suggests that antigens or other products responsible for protection are excreted into the medium.
In a separate experiment, on the other hand, when the P. aeruginosa 180 and P. aeruginosa 0:8 vaccines were injected at intervals of 16, 13, 10, and 7 days prior to the tail burn, rather than 3 and 2 days prior, only the specific vaccine significantly protected against the P. aeruginosa 180 challenge at 4 hr postburn.
Cross protection experiments with a rump burn. In the case of challenge with an extremely virulent organism such as P. aeruginosa 180 5 hr after the burn, prior injection of specific vaccines prepared either from cells or medium did not significantly protect a burned mouse when the area of the burn was increased from the tail to rump burn.
However, challenged with less-virulent Pseudomonas organisms, specific and nonspecific vaccines protected against the more severe burn. Effect of vaccine on mortality ofburned mice challenged locally with P. aeruginosa, Mills strain. Animals received 0.1 ml of vaccine, 0.85% NaCl, orfiltered brain heart broth subcutaneously 3 and 2 days prior to thermal trauma. Mice were given a rump burn at 70 C for 5 sec. After burning (5 hr), the rump area was dipped in a 10-1 dilution of a standard suspension of P. aeruginosa, Mills strain. In A, the animals were given a vaccine prepared from cells; in B, from the supernatant medium. The numbers in parentheses indicate the total number of mice studied in three separate experiments. Figure 1A demonstrates the significant protection afforded by a specific P. aeruginosa Mills cell vaccine, as well as by the nonspecific P. aeruginosa 180 cell vaccine, in burned mice given a Pseudomonas Mills challenge. The 21-day mortality for the saline controls was 93%; for the P. aeruginosa Mills cell vaccine, 25%; and for the P. aeruginosa 180 cell vaccine, 43%. In the same kind of experiment, but with supernatant vaccine instead (Fig. iB) , the 21-day mortality for the medium controls was 65%; for the P. aeruginosa Mills supernatant vaccine, 23%; and for the P. aeruginosa 180 supernatant vaccine, 38%.
In each of these cases, the specific vaccine gave the lowest mortality, but the nonspecific vaccine also showed a significant difference (P < 0.05) compared with the control. Filtered brain heart broth with Merthiolate also gave partial protection (P < 0.01) against the Pseudomonas challenge when compared with the saline controls. Figure 2 demonstrates cross protection of vaccines prepared from cells and medium in mice challenged with P. aeruginosa strain 0: 8. In Fig. 2A , significant protection (P < 0.05) over the control ( # 2) was afforded by both the specific undiluted P. aeruginosa 0:8 cell vaccine (#5) and the nonspecific undiluted P. aeruginosa 180 cell vaccine ( 4) and even by the 10-diluted cell vaccine of P. aeruginosa 0:8 ( # 3). On the other hand, the nonspecific 10-i diluted P. aeruginosa 180 (vaccine (#1) showed no protection.
In Fig. 2B , the specific supernatant vaccine ( 4) showed good protection after 21 days (P < 0.001), whereas the nonspecific P aeruginosa 180 supernatant vaccine (# 2) lowered the mortality from 48% to 32% during the same time period (P > 0.05). Boiling the supernatant 0:8 vaccine (# 3) did not significantly change the good protection by the unboiled vaccine. Filtered brain heart broth with Merthiolate ( #1) also gave partial protection (P > 0.05) against the Pseudomonas challenge when compared with the saline control ( #2, Fig. 2A ).
On the other hand, if the P. aeruginosa 180 and P. aeruginosa 0:8 vaccines were injected at intervals of 16, 13, 10, and 7 days prior to the rump burn, rather than 3 and 2 days prior, only the specific vaccine significantly protected against the P. aeruginosa 0: 8 challenge 4 hr postburn.
Vaccine administration after thermal trauma. Figure 3 shows the results of a P. aeruginosa 180 cell vaccine given immediately or 5 hr after burning and challenge with P. aeruginosa 180 at 5, 24, 48, and 72 hr postburn. There was significant protection by vaccine (administered immediately or at 5 hr postburn) when the challenge was given at 24 and 48 hr postburn (P < 0.01). When the challenge was given 5 hr postburn, the vaccines demonstrated no significant protection. Challenged at 24 hr, the vaccines lowered 21-day mortality from 80% to 38 to 43%; challenged at 48 hr, the vaccines decreased 21-day mortality from 60% to 7 to 9%; challenged at 72 hr, the control mortality was too low to show any effect by the vaccines.
When the burned animals were treated with a nonspecific Pseudomonas vaccine after the tail burn, the results were not quite as effective as those with the specific vaccine. Animals given P. aeruginosa 2915, P. aeruginosa Lawson, and P. (Table 3) .
On the other hand, when the burned animals were treated with an E. coli cell vaccine after the tail burn, there was no significant protection observed on challenge at 5, 24, 48, or 72 hr after challenge with P. aeruginosa 180.
When the severity of the burn was increased from the tail to the rump burn, the specific vaccine given after the burn was not as effective as after the tail burn. When the challenge was given 5, 24, 48, and 72 hr postburn, the specific vaccine showed no significant lowering of 21-day mortality. Nevertheless, when the challenge was given 96 hr after the burn, the specific P. aeruginosa 180 cell vaccine given immediately or 5 hr after the burn lowered the 21-day mortality from 95% to 62 to 67% (Fig. 4) . These differences show statistical significance (P < 0.01).
Additional experiments, in which a second or a Animals were given a tail burn at 70 C for 5 sec. Each vaccine group consisted of 40 mice. Vaccines were prepared from cells and were injected subcutaneously (0.1 ml) immediately or 5 hr after burn. Control mice received 0.1 ml of 0.85% NaCl subcutaneously immediately after the burn. Mice were challenged by dipping the burned tail in a standard suspension of Pseudomonas organisms at the time intervals indicated above.
b P < 0.02. third injection of 0.1 ml of P. aeruginosa 180 cell vaccine was administered 24 and 48 hr after the burn, showed no improvement on the results of only one injection of vaccine after the burn.
Autopsy findings. Macroscopic autopsy findings of animals that died after Pseudomonas challenge were the same as reported previously (13) . At 21 days, the survivors were autopsied, and the percentage of mice with renal abscesses was compiled in mice given the tail burn and vaccinated afterward. When a specific vaccine derived from Pseudomonas cells or supernatant fluid was given, the vaccinated animals showed a reduced percentage of renal abscesses compared to controls not vaccinated when challenged at 24, 48, and 72 hr after the burn. When a nonspecific Pseudomonas cell vaccine was given, the vaccinated mice also showed a reduced percentage of renal abscesses, but only when challenged at 48 and 72 hr postburn. DISCUSSION
The results of these experiments show that active immunization is effective in the prophylaxis of Pseudomonas septicemia in burned mice. The efficacy of vaccination depends upon the severity of the burn, the specificity of the vaccine, the virulence of the challenging organism, and the time of challenge in relation to the burn injury. Generally, a vaccine is most effective when it is specific, when the burn is not severe, when the challenging microorganism is not too virulent, and when there is a time lag between burn injury and challenge.
The results of these experiments agree with those published by us earlier with an intraperitoneal challenge (13) . In a different experimental model, Walker et al. (20) found that active immunization with some strains of Pseudomonas protected rats in which the undersurface of an autograft was seeded with Pseudomonas. The only other study in which vaccines were administered prophylactically in burned patients was published by Feller (2) . In a small group of 24 burned patients, he observed that a vaccine prepared from a single strain of P. aeruginosa administered after thermal injury decreased the incidence of septicemia due to Pseudomonas from 51 % to 29%; however, the control and vaccine groups were not compared during the same time period. He had even better success with the combined use of vaccine and human hyperimmune serum administered prophylactically in diminishing deaths and septicemia due to Pseudomonas; however, here again numbers were small, and comparison was made with nonsimultaneous controls. In conditions other than burns, there have been isolated reports in the literature in which patients with generalized Pseudomonas infections were treated with vaccines prepared from organisms isolated from wounds and organs. Some authors had success (5, 6), while others had none (4) .
These experiments also raise the question as to the mode of action of vaccination. Is the protective action due to antibody formation, to stimulation of the reticuloendothelial system, or to some unknown factor? In a previous report, we demonstrated that the primary and secondary antibody response to sheep erythrocytes was normal after burns of various degrees of severity in mice (12) . Other investigators have found similar results with other antigens (1, 8, 9) . We observed that antibody levels began to rise at 3 days and reached a high plateau at 4 to 5 days after antigenic stimulation. Two arguments in favor of antibody protection by vaccination are (i) specific vaccines were always more effective than nonspecific vaccines; and (ii) protection could be demonstrated in the more severe rump burn only when the challenge was given 4 days postburn, a time at which the antibody levels would be at their peak. Against the antibody argument in favor of a nonspecific protective effect on the reticuloendothelial system are: first, vaccine injected soon after the burn protected mice with the less severe tail burn when the challenge was given as early as 24 hr postburn. From the sheep erythrocyte studies, antibody levels were not sufficient at that time to protect against the challenge; second, vaccines prepared from E. coli and Proteus mirabilis were almost as effective as the nonspecific vaccines prepared from various 0 antigenic strains of P. aeruginosa after the tail burn. It seems unlikely that all gram-negative bacteria have a common antigen against antibodies to the virulent P. aeruginosa 180 to account for their effectiveness; and, third, vaccination schedules started 2 weeks prior to the burn, rather than 3 days prior, significantly protected only in the case of the animals given the specific vaccine. Antibody levels should be high after 2 weeks of immunization. Since these antibodies did not protect in the case of the nonspecific vaccine immunization, the protective action of the vaccine injected only 3 and 2 days prior to thermal trauma could have occurred by stimulation of the reticuloendothelial system. Of course, it is entirely probable that vaccines may act by a combination of these as well as other mechanisms.
Although burned mice do not usually die with Pseudomonas infections (11, 19) , the models described by Rosenthal (16) and us have been useful in therapeutic studies of Pseudomonas infections in burned mice. The protection provided by specific and nonspecific vaccines in burned mice challenged with P. aeruginosa suggests that the use of vaccines might be valuable as part of the therapy in the prevention of septicemia and death due to Pseudomonas in human burned patients. Since the encouraging results reported by Feller (2) with a monovalent vaccine alone are not entirely conclusive, further controlled prophylactic studies, perhaps with a polyvalent vaccine, should be undertaken in burned patients.
